32-2400

antibody from Invitrogen Antibodies

Targeting: CUL1

Provider product page for 32-2400

Western blot

Flow cytometry

Other assay

Antibody data

Antibody Data
Antigen structure
References [25]
Comments [0]
Validations
Western blot [3]
Flow cytometry [1]
Other assay [24]

Submit

Product number: 32-2400 - Provider product page
Provider: Invitrogen Antibodies
Product name: Cullin 1 Monoclonal Antibody (2H4C9)
Antibody type: Monoclonal
Antigen: Synthetic peptide
Description: CUL-1 Antibody (2H4C9), Prod# 32-2400 specifically detects neddylated and unmodified Cullin 1 in human cells.
Antibody clone number: 2H4C9
Concentration: 0.5 mg/mL

CUL1 protein structure - 32-2400 shown in red.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Western blot analysis was performed on whole cell, tissue extracts (30 µg lysate) of HEL 92.1.7 (Lane 1), MDA-MB-231 (Lane 2), NTERA-2 (Lane 3), MCF-7 (Lane 4), A549 (Lane 5), Caco-2 (Lane 6), Mouse Testis (Lane 7), Rat Testis (Lane 8) and Mouse pancreas (Lane 9). The blots were probed with Anti- CUL1 Mouse Monoclonal Antibody (Product # 32-2400, 1-2 µg/mL) and detected by chemiluminescence using Goat anti-Mouse IgG (H+L) Superclonal™ Secondary Antibody, HRP conjugate (Product # A28177, 0.4 µg/mL, 1:2500 dilution). A ~ 89 kDa band corresponding to CUL1 was observed across cell lines tested. Additionally ~25 kDa band was observed across mouse species. Known quantity of protein samples were electrophoresed using Novex® NuPAGE® 10 % Bis-Tris gel (Product # NP0302BOX), XCell SureLock™ Electrophoresis System (Product # EI0002) and Novex® Sharp Pre-Stained Protein Standard (Product # LC5800). Resolved proteins were then transferred onto a nitrocellulose membrane with Pierce™ Power Blotter System (Product # 22834). The membrane was probed with the relevant primary and secondary Antibody following blocking with 5 % skimmed milk. Chemiluminescent detection was performed using Pierce™ ECL Western Blotting Substrate (Product # 32106).

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Western blot analysis of Cullin-1 was performed by loading 10 µg of whole cell lysates from DMSO, MLN4924 or MG132 treated U2OS cells onto a SDS PAGE gel. Proteins were transferred, blocked and endogenous Cullin-1 was detected using a CUL-1 monoclonal antibody (Product # 32-2400) at a dilution of 1:1000.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Knockdown of CUL 1 was achieved by transfecting A549 cells with CUL 1 specific siRNAs (Silencer® select Product # s16055 and s228373). Western blot analysis (Fig a) was performed using whole cell extracts from the CUL 1 knock down cells (lane 3), non-specific scrambled siRNA transfected cells (lane 2) and untransfected cells (lane 1). The blots were probed with Anti-CUL 1 Mouse monoclonal Antibody (Product # 32-2400, 2µg/mL) and Goat anti-Mouse IgG (H+L) Superclonal™ Secondary Antibody, HRP conjugate (Product # A28177, 0.4 µg/mL, 1:5000 dilution). Densitometric analysis of this western blot is shown in histogram(Fig b). Loss of signal upon siRNA mediated knock down confirms that antibody is specific to CUL 1.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Fig. 2. FBXL16 is a cytoplasmic protein that binds SKP1 and PP2A but does not bind CUL1. A , expression of myc-FBXL16. Total cell lysate was prepared from 3T3 cells that were either mock-transfected or stably transfected with plasmids that contained the coding sequences for either myc-SKP2 or myc-FBXL16. Lysates were evaluated via SDS-PAGE followed by immunoblot with anti-myc. B , myc-FBXL16 is a cytosolic protein. Cytosolic (Cyt) and nuclear (Nuc) fractions prepared from 3T3 cells stably expressing myc-FBXL16 were fractionated by means of SDS-PAGE and immunoblotted for myc-FBXL16, alpha-actin (a cytosolic marker), and SP1 (a nuclear marker). C , myc-FBXL16 binds SKP1 and PP2A but not CUL1. Total cell lysates from 293 cells that were either mock-transfected or transfected with plasmids that contained the coding sequences for either myc-SKP2 or myc-FBXL16 were subjected to immunoprecipitation with anti-myc. Immunoprecipitates were fractionated via SDS-PAGE and immunoblotted with antibodies against SKP1, CUL1, and PP2A subunit A. D , FBXL16, but not SKP2, co-immunoprecipitates serine/threonine phosphatase activity. Total cell lysates from 293 cells that were either mock-transfected or transfected with plasmids that contained the coding sequences for myc-SKP2, myc-FBXL16, or HA-B55alpha (included as a positive control) were subjected to immunoprecipitation with either anti-myc (SKP2 and FBXL16) or anti-HA (B55alpha). Immunoprecipitates were assayed for their content of serine/th

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 3 Effect of SMIP004 on cell cycle pathways (A) RB subnetwork components downregulated by SMIP004 as revealed by Reactome network analysis (B) Kinetics and dose response of SMIP004 effects on RB pathway components as revealed by immunoblotting. LNCaP-S14 cells were treated with 40 muM SMIP004 for the indicated times (left panel) or were treated for 24 h with the indicated doses of the compound (right panel). (C) LNCaP-S14 cells were transfected with siRNA for PERK, followed by treatment with DMSO or SMIP004 (40 muM). The levels of cyclin D1, CDK4 and eIF2alpha-P were determined by immunoblotting. (D) Cells were pre-incubated with MG132 for 1h followed by treatment with SMIP004 for the indicated times. Cyclin D1 and CDK4 levels were analyzed by immunoblotting. (E) Cells were pre-treated with the neddylation inhibitor MLN4924 (1 muM) for 1h followed by treatment with SMIP004 (20 muM) for 6h. Levels of cyclin D1, CDK4, RB-P and cullin 1 (neddylated and unneddylated forms) were evaluated by immunoblotting. (F) LNCaP-S14 cells were transfected with p27 and p21 siRNAs for 24 h followed by transient transfection with cyclin D1 and CDK4 expression plasmids for another 24 h. Cells were then incubated for an additional 24 h in the presence or absence of SMIP004 (40 muM). Cells were collected for flow cytometry and immunoblotting analysis. Quantifications of phospho-RB levels are relative to the loading control actin. Short and long exposures are shown for cyclin D1 and CDK4 blots

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 1 USP9X binds, deubiquitylates, and stabilizes XIAP in mitosis Immunoblot analysis of HeLa cells using the indicated antibodies that were synchronized in G1/S phase using a double thymidine block or in mitosis using sequential thymidine and nocodazole treatment and collected at the given time points. Immunoblot analysis of HeLa cells that were transfected with siRNA oligonucleotides as indicated and left untreated or synchronized in mitosis using sequential thymidine and nocodazole treatment. Co-immunoprecipitation of XIAP and endogenous USP9X in HEK 293T cells that were transfected with FLAG-tagged XIAP or empty vector (EV) and synchronized in mitosis using nocodazole or left untreated. Co-immunoprecipitation of XIAP and endogenous USP9X in HEK 293T cells that were treated as in (C), but with additional transfection of the FLAG-tagged XIAP single amino acid mutants G188R and G188E. Only mitotic samples are shown. The asterisk denotes ubiquitylated forms of XIAP. In vivo ubiquitylation of XIAP in HeLa cells that were infected with the indicated expression constructs carrying FLAG-tagged XIAP and transfected with siRNA oligonucleotides as specified. Cells were synchronized in mitosis using sequential thymidine/nocodazole treatment, as indicated. Subsequent to treatment with MG132, whole-cell extracts (WCE) were prepared and ubiquitylated XIAP was isolated by anti-FLAG immunoprecipitation (IP) under denaturing conditions. Immunoblot analysis of NIH 3T3 cells that were tr

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure EV1 USP 9X interacts with XIAP in a direct manner and its active site binds to the BIR 2 domain of XIAP via glycine 188 In vitro co-immunoprecipitation of GST-purified XIAP with in vitro translated fragments of human USP9X with F2 containing the active site (aa 1556-1902). Co-immunoprecipitation of either full-length or different fragments of FLAG-tagged XIAP with endogenous USP9X from HEK 293T cells that were transfected with the indicated expression constructs and synchronized in mitosis using nocodazole. Immunoblot analyses of HeLa cells that were transfected with the indicated WT and mutant XIAP expression constructs and treated with cycloheximide (CHX) for the times specified. Co-immunoprecipitation of FLAG-tagged XIAP with endogenous USP9X from HEK 293T cells that were treated with BV6 as specified and nocodazole for 12 h. Source data are available online for this figure.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 2 USP9X stabilizes XIAP to antagonize mitotic cell death independent of MCL1 Immunoblot analysis of WT, Xiap -/- , Mcl1 -/- , or cIap2 -/- mouse embryonic fibroblasts that were lentivirally infected with shRNA constructs directed against a non-relevant mRNA (Ctrl) or against Usp9X mRNA and treated with taxol as specified. Two-dimensional cell cycle analysis (BrdU/PI) of cells described in (A). Sub-G1 and G2/M fractions of cells were quantified and averaged with two additional, independent experiments ( n = 3, +- SD; WT: ** P = 0.0016; *** P = 0.0004; Mcl1 -/- : *** P = 0.0003; ** P = 0.0017; cIap2 -/- : ** P = 0.0043, Student's t -test). Black bars exemplify shRNA Ctrl and white bars shRNA Usp9X samples. Immunoblot analysis of HeLa cells transfected with a FLAG-tagged USP9X expression construct or empty vector (EV) and treated with taxol for the indicated times. Immunoblot analysis of HeLa cells transfected with a FLAG-tagged XIAP expression construct or empty vector and treated as in (C). Two-dimensional cell cycle analysis (BrdU/PI) of cells described in (C) and (D). Apoptotic indices represent ratios of sub-G1 to G1/S cells and are shown for analyses at the indicated time points ( n = 3, +- SD). ** P = 0.0020; *** P = 0.0004; Student's t -test. Immunoblot analysis of HeLa cells that were transfected with siRNA oligonucleotides directed against a non-relevant mRNA (Ctrl) or against Xiap mRNA and treated with taxol as specified. Source data are available onl

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure EV2 USP 9X deubiquitylates XIAP - WT , but not XIAP -G188R or XIAP -G188E, in mitosis In vivo ubiquitylation of XIAP in HEK 293T cells that were co-transfected with the indicated expression constructs, synchronized in mitosis using nocodazole, and treated with MG132 prior to harvesting. The USP9X inhibitor WP1130 was added for 2 h as specified. XIAP was isolated by streptavidin affinity purification (AP) using denaturing conditions. HeLa cells were arrested in S phase with double thymidine block, released, and collected at the indicated time points. Deubiquitination activity was assessed by addition of HA-tagged dominant negative diubiquitin and following HA-IP under denaturing conditions. Immunoblot analysis of in vivo ubiquitylated XIAP (prepared as in A) using K48- or K63-specific ubiquitin antibodies. In vivo ubiquitylation of XIAP WT or XIAP G188R in HEK 293T cells that were co-transfected with the indicated expression constructs, synchronized in mitosis, and treated with MG132 as in (A). XIAP WT or XIAP G188R were isolated by anti-FLAG immunoprecipitation under denaturing conditions. In vivo ubiquitylation of XIAP WT or XIAP G188E in HEK 293T cells that were co-transfected with the indicated expression constructs and treated as in (A). XIAP WT or XIAP G188E were isolated by streptavidin affinity purification under denaturing conditions. Source data are available online for this figure.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure EV3 Mitotic stabilization of XIAP by USP 9X mediates resistance to spindle poisons Immunoblot analyses of the indicated DLBCL cell lines that were lentivirally transduced with IRES-GFP shRNA constructs against USP9X or a non-relevant mRNA, FACS sorted for GFP + PI - cells and exposed to doxorubicin for the indicated periods of time. Immunoblot analyses of the indicated DLBCL cell lines that were exposed to taxol for the indicated periods of time. Two hours before collecting, WP1130 at a concentration of 5 muM or DMSO was added as specified. FACS analysis (propidium iodide (PI) uptake) of DLBCL cell lines treated with taxol and/or the SMAC mimetic BV6 as indicated. Results displayed are from three independent experiments each ( n = 3, +- SD). ** P = 0.00643; Student's t -test. Immunoblot analyses of the indicated DLBCL cell lines that were treated with taxol or the SMAC mimetic BV6 as indicated. Source data are available online for this figure.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 1 Cell surface proteomics reveal a broad effect of IMiDs on transmembrane protein abundance and specify CD98hc/LAT1 as novel CRBN clients (A) Quantitative cell surface proteome of MM1s cells treated with lenalidomide versus solvent. MM1S cells were cultured in SILAC and control medium and subjected to treatment with 10 muM lenalidomide or DMSO for 48 h, followed by cell surface biotinylation, streptavidin affinity purification, and mass spectrometry (MS) analysis. Plasma membrane proteins (according to Gene Ontology cellular component [GOCC]) are depicted by blue circles. Solute carrier protein family members are marked by a yellow dot. Potential interactors of CRBN identified by tandem-affinity purification and MS are circled in red. (B) Representative immunoblot analysis of MM1S cells that were treated with DMSO, 10 muM lenalidomide (Len), 1 muM pomalidomide (Pom), or 100 muM thalidomide (Thal) for 72 h. (C) Representative immunoblot analysis of MM1S WT or MM1S with CRISPR-Cas9-mediated homozygous deletion of CRBN (clones T11 and T21). (D) Representative immunofluorescence images of HeLa cells that were transfected with constructs encoding both HA-CD98hc and FLAG-LAT1 and expressing the indicated short hairpin RNAs (shRNAs). Cells were stained with antibodies to HA (green) and FLAG (red), and DNA was stained with DAPI (blue). Scale bars, 10 mum. Quantification and confirmation of knockdown are presented in Figure S1 E. (E) Immunoprecipitation (IP) of FLAG-tagged LAT1

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 3 Conserved Role for NEDP1 in the DNA Damage-Induced Apoptosis (A) Western blotting of extracts from U2OS cells transfected with siRNAs and treated with the NEDD8 E1 inhibitor MLN4924 (1 muM, 15 h) as indicated. Extracts were re-analyzed with cullin-1 antibodies (right panel). (B) Western blot analysis of extracts from parental U2OS or U2OS NEDP1 knockout clones (C6 and H6). (C and D) Similar experiment as in (A), except cells were treated with IR (7 Gy) and analyzed either for caspase 3/7 activity (C) or AnnexinV staining (D) 9 h later. (E) Caspase 3/7 activity in parental or NEDP1 knockout U2OS cells exposed to etoposide for 15 h. Average values (n = 3) +- SEM. (F) MCF7 cells were irradiated with 2 or 10 Gy for the indicated times. Quantitative real-time PCR for NEDP1 was carried out as described in the STAR Methods . The experiments were performed in triplicates; average values +- SEM (left panel). Western blot analysis in extracts of MCF7 cells treated as indicated (right panel).